Clinical Study of Visibility Tinted Clariti Contact Lens

November 26, 2013 updated by: Sauflon Pharmaceuticals Ltd

The Clinical Performance of the Clariti Contact Lens (Including Handling Tint) for Daily Wear

The purpose of this study was to investigate the safety and efficacy of the Sauflon Clariti Monthly silicone hydrogel contact lenses with handling tint (Sauflon Pharmaceuticals Limited) by comparison with Air Optix Aqua silicone hydrogel lenses (Alcon Inc.)

Subjects used OptiFree Replenish solution (Alcon Lboratories Inc.) for daily lens maintenance, care and storage.

Study Overview

Status

Completed

Conditions

Detailed Description

I. Study characteristics:

The clinical study evaluates the clinical performance of a silicone hydrogel contact lens for daily wear, Clariti (including handling tint) (Sauflon Pharmaceuticals Ltd.) versus a predicate device, Air Optix Aqua (Alcon Inc.), in terms of lens performance, physiological response and subjective acceptance.

Subjects used OptiFRee Replenish solution (Alcon Laboratories Inc.) for daily lens maintenance, care and storage.

The key features were as follows:

  1. One month duration.
  2. Three investigator sites.
  3. Daily wear soft (hydrophilic) silicone hydrogel contact lenses, replaced on a monthly basis: Clariti Monthly (with handling tint)and Air Optix Aqua. Replenish was used as a care system by all subjects.
  4. A total of 38 subjects were enrolled, and 38 subjects accounted for 76 eyes were dispensed lenses. This group was randomized into 25 test subjects (50 eyes) and 13 control subjects (26 eyes).
  5. Of the 25 test subjects, 25 (100%) completed one month of use. Of the 13 control subjects, 12 (92.3%)completed one month of use.
  6. There were no adverse reactions.

II. Study period:

The study was conducted over one month of wear. Subjects were examined initially, and at two follow-up visits after two weeks and four weeks respectively. Study visits commenced on June 26, 2013 and completed on September 14, 2013.

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Manchester, United Kingdom, M60 1QD
        • Eurolens Research Faculty of Life Sciences The University of Manchester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 56 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • They are 18 years of age and above
  • They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent
  • They are willing and able to follow the protocol
  • The agree not to paticipate in other clinical research for the duration of this study
  • They have a best spectacle corrected visual acuity greater or equal to 20/25 (logMAR 0.1)
  • They have a manifest cylinder less than or equal to 0.75D
  • They have successfully worn contact lenses within six months of starting the study
  • They can be fitted with spherical soft contact lenses within the power range available
  • They are willing to wear the study lenses for a minimum of four days a week, six hours a day

Exclusion Criteria:

  • They have any active anterior segment ocular disease which would normally contraindicate contact lens wear
  • They have any anterior segment infection, inflammation or abnormality
  • They use any systemic medications which would normally contraindicate contact lens wear
  • They are using any ocular medications
  • They have a history of herpetic keratitis
  • They have a systemic disorder which would normally contraindicate contact lens wear
  • They have any infectious disease (e.g. Hepatitis) or any immunosuppressive disease (e.g. HIV)
  • They have glaucoma (high pressure in the eye), have had cataract surgery or a history of recurring abrasions
  • They have had corneal refractive surgery or they have an irregular cornea
  • They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus
  • They are pregnant or lactating
  • They have any slit lamp findings which are more serious than grade 1
  • They have a history of anaphylaxis or severe allergic reactions
  • They have taken part in any other contact lens or contact lens care product clinical trial or research, within two weeks prior to starting this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Air Optix Aqua
Compare safety and efficacy of the lens using OptiFree Replenish solution
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Active Comparator: Clariti with Handling Tint
Compare safety and efficacy of the lens using OptiFree Replenish solution
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Slit lamp Biomicroscopy
Time Frame: 1 month
Slit Lamp examination will be performed at the initial and follow-up visits. Slit lamp findings will be graded on a 0-4 scale (0=none;4=severe).
1 month
Adverse reactions
Time Frame: 1 month
Adverse reactions will be recorded throughout the study. Adverse recations will be classified as serious, significant and non-significant.
1 month
Wear Time
Time Frame: 1 month
Lens wear time is recorded for the two study lenses at follow-up visits.
1 month
Visual Acuity
Time Frame: 1 month
LogMAR Visual Acuity at high contrast will be recorded before and after performeing an over-refraction at the initial, two-week and one-month visits.
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective Scores
Time Frame: 1 month
Subjective scores for comfort, vision, handling and overall score will be recorded at the initial and follow-up visits. The subjective scores will be graded on a 0-5 scale.
1 month
Symptoms, problems and complaints
Time Frame: 1 month
The presence or absence of symptoms, problems and complaints will be recorded at two-weeks and one-month visits.
1 month
Discontinuations
Time Frame: 1 month
All subjects discontinuations will be recorded at the two-week and one-month visits.
1 month
Refraction
Time Frame: 1 month
Refraction was undertaken and recorded for all subjects at the initial, two-weeks and one-month visits.
1 month
Keratometry
Time Frame: 1 month
Keratometry measures will be performed at the initial and one-month visits for all subjects.
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (Actual)

July 1, 2013

Study Completion (Actual)

September 1, 2013

Study Registration Dates

First Submitted

November 7, 2013

First Submitted That Met QC Criteria

November 26, 2013

First Posted (Estimate)

November 27, 2013

Study Record Updates

Last Update Posted (Estimate)

November 27, 2013

Last Update Submitted That Met QC Criteria

November 26, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S13-540

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myopia

Clinical Trials on Air Optix Aqua

3
Subscribe